Sanofi/Ardelyx Ink Deal - Analyst Blog
February 25 2014 - 7:00PM
Zacks
Sanofi (SNY) entered into an agreement with a
biopharmaceutical company, Ardelyx Inc. to license the latter’s
novel phosphate transport NaP2b inhibitor program. The program
includes a number of candidates in early stages of development for
the treatment of hyperphosphatemia in patients suffering from end
stage renal disease or chronic kidney disease.
As per the terms, Sanofi will undertake the sole responsibility of
developing the candidates further while Ardelyx will retain an
option to co-promote the drugs, covered under the agreement, in the
U.S.
Sanofi will make an undisclosed upfront payment to Ardelyx.
Additionally, Sanofi will be obligated to make development and
regulatory milestone payments of up to $198 million depending upon
the achievement of certain targets. Ardelyx will also receive
royalties on net product sales.
Our Take
We are pleased with Sanofi’s efforts to boost its pipeline.
Although Sanofi has some promising pipeline candidates (U300,
alirocumab and sarilumab), we are disappointed with the string of
pipeline setbacks at the company in the recent past. The Complete
Response Letter (CRL) for its multiple sclerosis drug, Lemtrada,
was a huge disappointment for Sanofi.
We remind investors that Sanofi has been quite active on the
deal-making front, particularly with biopharmaceutical companies.
Earlier this year, Sanofi expanded its existing agreement with
Alnylam Pharmaceuticals, Inc. (ALNY) for the
development of treatments for rare genetic diseases. Additionally,
Sanofi announced its plan to acquire a 12% stake in Alnylam through
a $700 million investment.
Meanwhile, Sanofi has been showing a lot of interest in
Regeneron Pharmaceuticals, Inc. (REGN). Sanofi
intends to increase its stake in the latter.
Sanofi carries a Zacks Rank #5 (Strong Sell). Some better-ranked
stocks include Forest Laboratories (FRX). Forest
Labs carries a Zacks Rank #1 (Strong Buy).
ALNYLAM PHARMA (ALNY): Free Stock Analysis Report
FOREST LABS A (FRX): Free Stock Analysis Report
REGENERON PHARM (REGN): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2023 to Sep 2024